Correction: ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-18-4270
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Treating ER+ Breast Cancer With CDK4/6 Inhibitors

Cancer Discovery
Oncology
2017English

Loss of FAT1 Drives Resistance to CDK4/6 Inhibitors in Breast Cancer

Cancer Discovery
Oncology
2018English

CDK4/6 Inhibitors: Promising Opportunities Beyond Breast Cancer

Cancer Discovery
Oncology
2016English

CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer

Cancer Cell
Cancer ResearchOncologyCell Biology
2016English

Inhibitors Targeting CDK4/6, PARP and PI3K in Breast Cancer: A Review

Therapeutic Advances in Medical Oncology
Oncology
2018English

Correction: CDK4/6 Inhibitors in the Treatment of Patients With Breast Cancer: Summary of a Multidisciplinary Round-Table Discussion

ESMO Open
Cancer ResearchOncology
2019English

Stromal Senescence by Prolonged CDK4/6 Inhibition Potentiates Tumor Growth

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2016English

Cdk4/6 Inhibitors and Overall Survival: Power of First-Line Trials in Metastatic Breast Cancer

npj Breast Cancer
OncologyRadiologyNuclear MedicinePharmacologyImaging
2018English

Distinct P53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers

Clinical Cancer Research
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy